

# Referencias

1. (70). OMS. The optimal duration of exclusive breastfeeding. Results of a WHO systematic review. Número de referencia OMS: WHO/NHD/01.08 WHO/FCH/CAH/01.23.
2. (7). Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding (Review). Cochrane Database Syst Rev. 2002; 1: CD003517.
3. (45). Martín R, Langa S, Reviriego C, Jiménez E, Marín ML, Xaus J, Fernández L, Rodríguez JM. Human milk is a source of lactic acid bacteria for the infant gut. *J Pediatr*. 2003; 143(6):754-8.
4. (35). Rodríguez JM, Jiménez E, Merino V, Maldonado A, Marín ML, Fernández L, Martín R. Microbiota de la leche humana en condiciones fisiológicas. *Acta Pediatr Esp*. 2008; 66(2): 77-82.
5. (34). Rodríguez JM, Dalmau J. Probióticos para el binomio madre-hijo (I). *Acta Pediatr Esp*. 2007; 65(9): 452-457.
6. (14). Lara-Villoslada F, Olivares M, Sierra S, Rodríguez JM, Boza J, Xaus J. Beneficial effects of probiotic bacteria isolated from breast milk. *Br J Nutr*. 2007; 98 Suppl 1:S96-100.
7. (106). Sámano R, Martínez-Rojano H, Godínez Martínez E, Sánchez Jiménez B, Villeda Rodríguez GP, Pérez Zamora J et al. Effects of breastfeeding on weight loss and recovery of pregestational weight in adolescent and adult mothers. *Food Nutr Bull*. 2013; 34(2): 123-130.
8. (107). Chua S, Aralkuraran S, Lim L. Influence of breastfeeding and nipple stimulation in postpartum uterine activity. *Brit J Obstet Gynaec*. 1994; 101: 804-805.
9. (108). Rosenblatt K, Thomas D. WHO Collaborative study of neoplasia and steroid contraceptives. *Int J Epidemiol*. 1993; 22: 192-197.
10. (109). Newcomb P, Storer B, Longnecker M. Lactation and a reduced risk of premenopausal breast cancer. *New Engl J Med*. 1994; 330: 81-87.
11. (110). Cumming R, Klineberg R. Breastfeeding and other reproductive factors and the risk of hip fractures in elderly women. *Int J Epidemiol*. 1993; 22: 684-691.
12. (37). Hernández MT, Lasarte JJ, Lozano MJ, Aguayo J, Díaz NM. Lactancia materna dolorosa: estrategias de tratamiento para el pediatra. *Acta Pediatr Esp*. 2008; 66(10): 504-509.
13. (32). OMS. Mastitis. Causas y manejo. Número de referencia OMS: WHO/FCH/CAH/00.13. 2000.
14. (160). Anderson JE, Held N, Wright K. Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding. *Pediatrics*. 2004; 113(4): e360-e364.
15. (161). Strong GD, Mele N. Raynaud's phenomenon, candidiasis, and nipple pain. Strategies for differential diagnosis and care. *Clinical Lactation*. 2013; 4(1): 21-27.
16. (15). Contreras GA, Rodríguez JM. Mastitis: comparative etiology and epidemiology. *J Mammary Gland Biol Neoplasia*. 2011;16(4):339-56.
17. (39). Delgado S, Arroyo R, Jiménez E, Fernández L, Rodríguez JM. Mastitis infecciosas durante la lactancia: un problema infravalorado (I). *Acta Pediatr Esp*. 2009; 67(2):77-84.
18. Díaz M. Iniciativa mundial de lactancia materna. Encuesta nacional de hábitos de lactancia [pdf]. The Global Breastfeeding Initiative; 2013. Disponible en: [www.aeped.es/default/files](http://www.aeped.es/default/files).
19. (91). Barbosa-Cesnik C, Schwartz K, Foxman B. Lactation mastitis. *JAMA*. 2003 Apr 2; 289(13):1609-12.

20. (40). Jiménez E, Delgado S, Arroyo R, Fernández L, Rodríguez JM. Mastitis infecciosas durante la lactancia: un problema infravalorado (y II). *Acta Pediatr Esp.* 2009; 67(3):125-32.
21. (55). Foxman B. Lactation mastitis: occurrence and medical management among 946 breastfeeding women: in the United States. *Am J Epidemiol.* 2002; 155(2):103-14.
22. (100). Arroyo R, Mediano P, Jiménez E, Delgado S, Fernández L, Marín M, et al. Diagnóstico etiológico de las mastitis infecciosas: propuesta de protocolo para el cultivo de muestras de leche humana. *Acta Pediatr Esp.* 2011; 69: 276-281.
23. (16). Carrera M, Arroyo R, Mediano P, Fernández L, Marín M, Rodríguez JM. Lactancia materna y mastitis. Tratamiento empírico basado en la sintomatología y los agentes etiológicos. *Acta Pediatr Esp.* 2012; 70(6): 255-261.
24. (58). Berens P, Swaim L, Peterson B. Incidence of methicilin-resistant *Staphylococcus aureus* in postpartum breast abscesses. *Brestfeed Med.* 2010; 5 (3):113-5.
25. (72). Moazzez A, Kelso RL, Towfigh S, Sohn H, Berne TV, Mason RJ. Breast abscess bacteriologic features in the era of community acquired methicillin-resistant *Staphylococcus aureus* epidemics. *Arch Surg.* 2007; 142: 881-884.
26. (22). Delgado S, Arroyo R, Jiménez E, Marín ML, del Campo R, Fernández L, Rodríguez JM. *Staphylococcus epidermidis* strains isolated from breast milk of women suffering infectious mastitis: potential virulence traits and resistance to antibiotics. *BMC Microbiol.* 2009; 9:82.
27. (73). Paviour S, MUSAAD S, Roberts S, Taylor G, Taylor S, Shore K, et al. *Corynebacterium* species isolated from patients with mastitis. *Clin Infect Dis.* 2002; 35: 1.434-1.440.
28. (74). Bercot B, Kannengiesser C, Oudin C, Grandchamp B, Sanson-le Pors MJ, et al. First description of NOD2 variant associated with defective neutrophil responses in a woman with granulomatous mastitis related to corynebacteria. *J Clin Microbiol.* 2009; 47:3.034-3.037.
29. (75). Martineau F, Picard FJ, Lansac N, Menard C, Roy PH, Ouellette M, et al. Correlation between the resistance genotype determined by multiplex PCR assays and the antibiotic susceptibility patterns of *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Antimicrob Agents Chemother.* 2000; 44: 231-238.
30. (71). Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al. SENTRY Participants Group. Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clin Infect Dis.* 2001; 32 Supl 2: 114-132.
31. (1). Arroyo R, Martín V, Maldonado A, Jiménez E, Fernández L, Rodríguez JM. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of *Lactobacilli* isolated from breast milk. *Clin Infect Dis.* 2010; 50(12):1551-8.
32. (51). Fonollá Joya J, Maldonado Lobón JA, Díaz López MA, Bañuelos Hortigüela O, Olivares Martín M. *Lactobacillus fermentum* CECT5716 reduce la carga de *Staphylococcus* en la leche materna y mejora la sintomatología en mujeres con dolor en el pecho durante la lactancia. SAMEM, 2014.
33. (101). Carmichael AR, Dixon JM. Is lactation mastitis and shooting breast pain experienced by women during lactation caused by *Candida albicans*? *Breast.* 2002; 11: 88-90.
34. (102). Francis-Morrill J, Heinig MJ, Pappagianis D, Dewey KG. Diagnostic value of signs and symptoms of mammary candidiasis among lactating women. *J Hum Lact.* 2004; 20: 288-295.

35. (112). Mediano P, Fernández L, Rodríguez JM, Marin M. Case-control study of risk factors for infectious mastitis in Spanish breastfeeding women. *BMC Pregnancy Childbirth*. 2014; 6(14): 195-204.
36. (162). Comisión Lactancia Materna MINSAL – UNICEF. La leche humana, composición, beneficios y comparación con la leche de vaca. En: Manual de lactancia para profesionales de la salud [Internet]. Chile. Shellhorn C, Valdés V. 1995. Disponible en: [www.unicef.cl/lactancia/mod01/](http://www.unicef.cl/lactancia/mod01/)
37. Recomendaciones sobre lactancia materna del Comité de Lactancia Materna de la Asociación Española de Pediatría. <http://www.aeped.es/comite-lactancia-materna/documentos/recomendacionessobre-lactancia-materna-comite-lactancia-materna>.
38. (77). Fernández L, Langa S, Martín V, Maldonado A, Jiménez E, Martín R, Rodríguez JM. The human milk microbiota: origin and potential roles in health and disease. *Pharmacol Res*. 2013 Mar; 69(1):1-10.
39. (2). Heikkilä MP, Saris PE. Inhibition of *Staphylococcus aureus* by the commensal bacteria of human milk. *J Appl Microbiol*. 2003; 95(3):471-8.
40. (155). Rodríguez JM. The origin of human milk bacteria: is there a bacterial entero-mammary pathway during late pregnancy and lactation? *Adv. Nutr*. 2014; 5: 779-784.
41. (79). Dasayanake AP, Li Y, Wiener H, Ruby JD, Lee MJ. Salivary *Actinomyces naeslundii* genospecies 2 and *Lactobacillus casei* *leves* predict pregnancy outcomes. *J Periodontol*. 2005; 76: 171-177.
42. (78). Vázquez-Torres A, Jones-Carson J, Baumler AJ, Falkow S, Valdivia R, Brown W, et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. *Nature*. 1999; 401: 804-808.
43. (93). Pérez PF, Dore J, Leclerc M, Lévesse F, Benyacoub J, Serrant P, et al. Bacterial imprinting of the neonatal immune system: lessons from maternal cells? *Pediatrics*. 2007; 119: 724-732.
44. (94). Bertotto A, Gerli R, Castellucci G, Scalise F, Vaccaro R. Human milk lymphocytes bearing the gamma/delta T-cell receptor are mostly delta TCS1-positive cells. *Immunology*. 1991; 74: 360-361.
45. (36). Olivares M, Lara-Villoslada F, Sierra S, Boza J, Xaus J. Efectos beneficiosos de los probióticos de la leche materna. *Acta Pediatr Esp*. 2008; 66(4): 183-188.
46. (84). Beasley SS, Saris, PEJ. Nisin-producing *Lactococcus lactis* strains isolated from human milk. *Appl Environ Microbiol*. 2004; 70: 5.051- 5.053.
47. (68). Martín R1, Olivares M, Marín ML, Fernández L, Xaus J, Rodríguez JM. Probiotic potential of 3 Lactobacilli strains isolated from breast milk. *J Hum Lact*. 2005 Feb; 21(1):8-17; quiz 18-21. 41.
48. (49). R. Martín, E. Jiménez, M. Olivares, M.L. Marín, L. Fernández, J. Xaus, J.M. Rodríguez. *Lactobacillus salivarius* CECT 5713, a potential probiotic strain isolated from infant feces and breast milk of a mother-child pair. *International Journal of Food Microbiology*. 112 (2006) 35-43.
49. (88). Cesar JA, Victoria CG, Barros FC, et al. Impact of breast feeding on admission for pneumonia in postneonatal period in Brazil: nested case-control study. *J Nutr*. 2005; 51: 1.286-1.288.
50. (98). Victoria CG, Smiyh PG, Vaughan JP, et al. Evidence for protection by breast-feeding against infant deaths from infectious diseases in Brazil. *Lancet*. 1987; 2: 319-322.
51. (87). Nascimento MBR. Breastfeeding: making the difference in the development, health and nutrition of term and preterm newborns. *Rev Hosp Clin Fac Med S Paulo*. 2003; 58: 49-60.
52. (52). Kalliomäki M. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. *Lancet*. 2001 Apr 7; 357(9262):1076-9.

53. (99). Hahn-Zoric M, Fulconis F, Minoli L, et al. Antibody response to parenteral and oral vaccines are impaired by conventional and low protein formulas as compared to breast-feeding. *Acta Paediatr Scand.* 1990; 79: 1.137-1.142.
54. (86). Kirjavainen PV, Apostolou E, Arvola T, Salminen SJ, Gibson GR, Isolauri E. Breastfeeding: making the difference in the development, health and nutrition of term and preterm newborns. *Rev Hosp Clin Fac Med S Paulo.* 2003; 58: 49-60.
55. (151). Guarner F, Khan A, Garisch J, Eliakim R, Gangl A, Alan T et al. WGO Practice Guideline: Probiotics and probiotics [Internet]. WGO; 2011. Disponible en: [www.worldgastroenterology.org/probiotics-prebiotics.html](http://www.worldgastroenterology.org/probiotics-prebiotics.html)
56. (43). Sanz Y, Collado MC, Dalmau J. Probióticos: criterios de calidad y orientaciones para el consumo. *Acta Pediatr Esp.* 2003; 61(9):476-482.
57. (92). López-Alarcón M, Villalpando S, Fajardo A. Breastfeeding lowers the frequency and duration of acute respiratory infection and diarrhea in infants under six month of age. *J Nutr.* 1997; 127:436- 443.
58. (95). Wright AL, Bauer M, Naylor A, Sutcli e E , Clark L. Increasing breastfeeding rates to reduce infant illness at the community level. *Pediatrics.* 1998; 101: 837-844.
59. (3). Jiménez E, Fernández L, Maldonado A, Martín R, Olivares M, Xaus J, Rodríguez JM. Oral administration of *Lactobacillus* strains isolated from breast milk as an alternative for the treatment of infectious mastitis during lactation. *Appl Environ Microbiol.* 2008;74(15):4650-5.
60. (18). Lara-Villoslada F, Sierra S, Díaz-Ropero MP, Rodríguez JM, Xaus J, Olivares M. Safety assessment of *Lactobacillus fermentum* CECT5716, a probiotic strain isolated from human milk. *J Dairy Res.* 2009; 76(2):216-21.
61. (4). Puleva Biotech. Hereditum, una nueva generación de bacterias probióticas aisladas de leche materna.
62. (12). Olivares M, Díaz-Ropero MP, Sierra S, Lara-Villoslada F, Fonollá J, Navas M, Rodríguez JM, Xaus J. Oral intake of *Lactobacillus fermentum* CECT5716 enhances the effects of inuenza vaccination. *Nutrition.* 2007 Mar; 23(3):254-60.
63. (6). Maldonado J, Cañabate F, Sempere L, Vela F, Sánchez AR, Narbona E, López-Huertas E, Geerlings A, Valero AD, Olivares M, Lara-Villoslada F. The human milk probiotic *Lactobacillus fermentum* CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. *J Pediatr Gastroenterol Nutr.* 2012; 54(1):55-61.
64. (59). Gil-Camposa, M. *Lactobacillus fermentum* CECT 5716 is safe and well tolerated in infants of 1–6 months of age: A Randomized Controlled Trial. *Pharmacological Research.* 2012; 65: 231-238.a